PCRX

Pacira Biosciences, Inc. (PCRX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Pacira Biosciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies, primarily through its commercial products EXPAREL (postsurgical pain) and ZILRETTA (osteoarthritis knee pain). The company is advancing clinical programs including PCRX-201 (gene therapy for OA) and PCRX-2002 (long-acting ropivacaine). A significant strategic event during this period was the agreement to divest its iovera cryoanalgesia business to Zimmer, Inc., which closed on July 31, 2026.

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: Gross margin for the six months ended June 30, 2026, was 78%.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 6% year-over-year (YoY) to $369.8 million. Net product sales rose 6% to $367.9 million, driven by 4% growth in EXPAREL and 9% growth in ZILRETTA. Royalty revenue decreased 8% YoY.
• Profitability: The company reported a net income of $7.6 million for the six months ended June 30, 2026, compared to a net loss of $35,000 in the same period in 2025. This turnaround was significantly aided by a discrete income tax benefit of $6.4 million related to the reversal of a U.K. valuation allowance.
• Operating Expenses: Total operating expenses increased 6% YoY to $358.6 million. This included $5.9 million in divestiture-related expenses for the iovera sale. Research and Development (R&D) expenses increased 8% YoY, while Selling, General, and Administrative (SG&A) expenses increased 6% YoY.
• Divestiture: Assets and liabilities related to iovera were reclassified as "held for sale" in Q2 2026. The transaction closed in July 2026 with an upfront cash receipt of $73.6 million.

Guidance, Outlook, and Risks

• Strategic Focus: Management is transitioning to focus on core biopharmaceutical assets (EXPAREL, ZILRETTA, and the HCAd gene therapy platform) following the iovera divestiture.
• Commercial Updates: UnitedHealthcare now provides separate reimbursement for EXPAREL, expanding access to approximately 150 million covered lives. A co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA is active.
• Development Pipeline: The company is screening subjects for Part B of the Phase 2 ASCEND study for PCRX-201. Topline data from Part A is expected by the end of 2026.
• Tariff Risks: The company notes potential negative impacts on gross margins due to U.S. tariffs on pharmaceutical products imported from the E.U. and U.K., where its API and finished goods are sourced. The magnitude of this impact is currently unquantifiable due to policy volatility.
• Legal Contingencies: The company is defending patent infringement suits filed by WhiteOak and Qilu regarding generic EXPAREL. A previous settlement with eVenus was finalized in 2025.
• Capital Allocation: The company has $100 million remaining under its $300 million share repurchase program, which expires December 31, 2026. It repurchased $50.4 million of stock in the first half of 2026.

Investor Verification Checklist

• Divestiture Closing: Verify the final cash proceeds and any adjustments from the iovera sale to Zimmer, which closed post-period end (July 31, 2026).
• Tariff Impact: Monitor updates on U.S. tariff policies regarding pharmaceutical imports from the U.K. and E.U. to assess potential margin compression.
• PCRX-201 Data: Await topline data from the Phase 2 ASCEND study (expected late 2026) to validate the gene therapy pipeline.
• Patent Litigation: Track the status of the WhiteOak and Qilu patent infringement suits regarding EXPAREL.
• Debt Structure: Review the terms of the 2029 Convertible Senior Notes ($287.5 million principal) and the Revolving Credit Facility ($81 million outstanding) for conversion triggers and covenant compliance.